US FDA's chief medical and science officer Prasad departs agency
"Dr. Prasad did not want to be a distraction to the great work of the FDA in the Trump administration and has decided to return to California and spend more time with his family," an HHS spokesperson said in an emailed statement to Reuters.
"We thank him for his service and the many important reforms he was able to achieve in his time at FDA.'
STAT News first reported about Prasad's departure, saying it came after a number of controversial decisions by the FDA regarding a gene therapy drug for the treatment of Duchenne muscular dystrophy manufactured by Sarepta Therapeutics (SRPT.O), opens new tab.
The agency first halted shipments of the drug, called Elevidys, after the deaths of some recipients but rescinded the suspension on Monday.
In June, STAT News reported that Prasad was named as the health regulator's chief medical and science officer, citing an internal memo.
In May, the FDA named Prasad, an oncologist who previously criticized FDA leadership and COVID-19 mandates, as the director of its Center for Biologics Evaluation and Research.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
an hour ago
- Reuters
US FDA says country's IV, injectable saline shortage is resolved
Aug 8 (Reuters) - A shortage of intravenous and injectable saline solutions in the United States has now been resolved, U.S. Food and Drug Administration commissioner Martin Makary said on Friday. The shortage partly stems from Baxter International's (BAX.N), opens new tab North Carolina plant getting damaged in Hurricane Helene last year. At that time, the Marion, North Carolina site was producing 60% of the nation's supply of IV fluids and peritoneal dialysis solutions, amounting to 1.5 million bags daily, according to the American Hospital Association. A shortage of IV fluids, which provide nutrients to the body or replenish fluids lost due to injury or illness, had forced hospitals to curtail elective procedures.
Medical News Today
3 hours ago
- Medical News Today
Does Ozempic cause cancer?
Ozempic (semaglutide) carries a boxed warning for thyroid cancer based on animal studies. Here's what to know about the drug's cancer risk and what current research is a prescription drug that doctors prescribe to treat type 2 diabetes and help lower the risk of certain heart and kidney problems. They may prescribe it off-label to support weight loss. (Off-label use means prescribing a drug for a purpose other than what it's been approved for.)If you've seen warnings about a possible link between Ozempic and cancer, you may be wondering if this drug could raise your cancer risk. Here's what you need to know about Ozempic and cancer, including what research has shown so far.»Learn about Ozempic, including its dosage, side effects, and more, in this Ozempic overview article. Ozempic and thyroid cancerOzempic carries a boxed warning for a possible risk of thyroid cancer. A boxed warning is the most serious type of warning required by the Food and Drug Administration (FDA). This warning is based on animal studies, where some rats developed thyroid tumors after receiving semaglutide (the active ingredient in Ozempic). However, animal studies don't always predict a drug's effects in humans. It's important to note that no cases of thyroid cancer were reported in clinical trials of Ozempic. But because of the findings in animals, the FDA requires this warning for the to this possible risk, Ozempic is not usually prescribed for people who have either:a personal or family history of medullary thyroid cancera rare genetic condition called multiple endocrine neoplasia type 2 (MEN2)These conditions may increase the risk of thyroid cancer. Your doctor will likely recommend a different treatment option if you have one of these cancer symptomsTalk with your doctor if you notice symptoms of thyroid cancer while receiving Ozempic. These may include:difficulty swallowinghoarseness or voice changespersistent cougha lump or swelling in the neckThese symptoms don't always mean cancer is present. However, your doctor may want to run tests to check for any signs of risk percentagesThere are no confirmed cancer risk percentages for people using Ozempic. The drug's warning about thyroid cancer is based on animal research.A recent research review involving Ozempic for type 2 diabetes and obesity found no apparent increase in thyroid cancer more research would help fully understand any long-term and breast cancerClinical trials of Ozempic have not shown an increased risk of breast works by mimicking a natural hormone called glucagon-like peptide-1 (GLP-1), which helps manage blood sugar and appetite. While GLP-1 receptors (attachment sites) are primarily found in the digestive system, they're also present in other parts of the body. This includes breast of this, some earlier studies raised concerns about whether GLP-1 medications could affect breast tissue and increase the risk of breast cancer. However, more recent research does not show a clear link between Ozempic and breast Ozempic cause breast cancer?To date, there's no strong evidence to suggest that Ozempic causes breast cancer. If you have a personal or family history of breast cancer, talk with your doctor. They can help you weigh the benefits and potential risks of treatment based on your health asked questionsKeep reading for answers to some frequently asked questions about Ozempic and Ozempic cause prostate problems?Ozempic is not known to cause prostate problems, including prostate cancer or an enlarged prostate.A research review suggests that GLP-1 receptor agonists may help lower the risk of prostate cancer. (Ozempic is a GLP-1 receptor agonist.) However, more research would help in understanding this possible you have other concerns about Ozempic and prostate health, talk with your doctor. Does Ozempic affect thyroid levels?Ozempic is not known to directly affect thyroid hormone levels, such as thyroid-stimulating hormone(TSH).However, Ozempic does carry a boxed warning about the risk of thyroid tumors based on findings from animal studies. While this risk hasn't been confirmed in humans, your doctor may still monitor your thyroid health more closely during treatment. They may order blood tests to check your thyroid hormone levels or watch for symptoms of thyroid problems. If you have an existing thyroid condition or concerns about your thyroid health while using Ozempic, talk with your no confirmed evidence that Ozempic causes cancer in humans. However, the drug does carry a boxed warning about thyroid cancer based on animal studies. Although this risk has not been observed in humans, doctors may be cautious about prescribing Ozempic to people with certain thyroid you're using Ozempic or considering it, talk with your doctor about your health history and any concerns about cancer you may have. They can help determine whether Ozempic is the right treatment option for you.
Scottish Sun
5 hours ago
- Scottish Sun
Brits fast-tracked onto NHS trial of ‘game-changing' cancer vaccine to combat sex-related cases
'These cancer vaccines could be game-changing for patients facing some of the most challenging diagnoses,' one expert says PEOPLE with head and neck cancer will be given fast-track access to a new "transformative" cancer jab. The injection targets advanced forms of the devastating disease, giving patients "renewed hope of holding it at bay". Advertisement 2 More than 100 patients are expected to be recruited onto the trial Credit: PA It works by boosting the immune system's response by using Covid jab-style mRNA technology helping it 'attack' cancer cells containing human papillomavirus (HPV) proteins. Up to 70 per cent of all head and neck cancers are linked to HPV, a virus often spread via sex. This move adds to the NHS England's Cancer Vaccines Launch Pad programme, which has already helped 550 bowel and skin cancer patients. More than 100 patients with advanced head and neck cancer are expected to benefit from the jab through the AHEAD-MERIT (BNT113) trial, running at 15 hospitals over the next year. Advertisement Head and neck cancer is a general term to describe forms of the disease in those regions of the body, and can include cancer of the mouth, throat or voice box. Around 11,000 new cases are diagnosed in England every year. HPV is a common virus spread through close contact, including sex and childbirth. Advertisement Most HPV infections clear naturally without causing symptoms. 'Low-risk' types may cause warts, like genital warts or verrucas on hands and feet. But at least 14 'high-risk' types can sometimes trigger cancer. Rock star devastated as he's diagnosed with 'very aggressive' cancer and shares snap from hospital bed Despite treatment advances, aggressive head and neck cancers remain tough to beat, with high recurrence rates and less than 50 per cent surviving beyond two years. Advertisement The vaccine used in the study has been designed to create two proteins that are commonly found in head and neck cancers associated with high-risk types of HPV. These types of cancer, known as squamous cell cancers, develop from flat, scale-like cells in the outer layer of the skin and other areas of the body. Health minister Karin Smyth described the plan as a "massive win for cancer patients". She added: "These cancer vaccines could be game-changing for patients facing some of the most challenging diagnoses. Advertisement "By getting these trials running in our NHS, we're putting ourselves at the forefront of medical innovation, improving outcomes for people living with cancer." NHS England has joined forces with life sciences company BioNTech to help identify potentially eligible patients to refer to NHS hospitals running the trial. 2 The trial is the third to be run through the NHS Cancer Vaccine Launch Pad, which is supported by the Cancer Research UK-funded Southampton Clinical Trials Unit. Advertisement Professor Peter Johnson, national clinical director for cancer at NHS England, said: "It's fantastic that more patients with advanced head and neck cancers will now be able to access this potentially transformative vaccine, offering renewed hope of holding the disease at bay." Tamara Kahn, chief executive at Oracle Head & Neck Cancer UK, said the trial "offers crucial hope to those living with advanced stages of cancer". "While we advocate for HPV vaccination to prevent these cancers, those already fighting this devastating disease urgently need new treatments that could mean more time with loved ones," she added. 'It'll allow people to get on with their lives' Chris Curtis was diagnosed with HPV-related head and neck cancer in 2011 and set up a support charity, The Swallows. Advertisement The 67-year-old, from Blackpool, said: "As a survivor of HPV-related head and neck cancer, I know first-hand the physical, emotional, and psychological toll this disease takes not just on the patient, but on the entire support system around them. "With this aggressive cancer you live in the fear of reoccurrence every day - so anything that could help control the disease or give people peace of mind is groundbreaking - it'll allow people to get on with their lives and move forward." The Cancer Vaccine Launch Pad - a partnership between NHS England, the Government and BioNTech - has already helped refer about 550 patients to trials for vaccines for bowel and skin cancers. Dr Iain Foulkes, executive director of research and innovation at Cancer Research UK, said: "The Cancer Vaccines Launch Pad is an important route to fast-track promising mRNA vaccine technology into clinical trials. Advertisement "Research into personalised cancer treatments is vital. "There are over 200 different types of cancer and it's unlikely there will ever be a single cure that works for everyone. "That's why it's vital that we support a wide range of research, so that more people can live longer, better lives, free from the fear of cancer."
